NCCTG N0543 (Alliance): A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma

BACKGROUND: Oxaliplatin in combination with either 5-fluorouracil or capecitabine is commonly used as first line therapy for small bowel adenocarcinoma. The addition of irinotecan improves survival in other gastrointestinal tumors but at the cost of hematologic toxicity. We performed a phase II, coo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: McWilliams, Robert R., Foster, Nathan R., Mahoney, Michelle R., Smyrk, Thomas C., Murray, Joseph A., Ames, Matthew M., Horvath, Elise, Schneider, Daniel, Hobday, Timothy J., Jatoi, Aminah, Meyers, Jeffrey P., Goetz, Matthew P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5589489/
https://ncbi.nlm.nih.gov/pubmed/28493308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30766
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados